Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis US Small Cap Value ETF (AVUV) vs Novo Nordisk A/S (NVO) Price & Performance

Avantis US Small Cap Value ETFTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Avantis US Small Cap Value ETF vs Novo Nordisk A/S — how do they compare? Avantis US Small Cap Value ETF trades at $127.78, while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Avantis US Small Cap Value ETF pays none, and Avantis US Small Cap Value ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

AVUVNVO
Sector
Sector/ThematicHealth
52-Week High
$128.74$63.98
52-Week Low
$93.93$35.29
Market Cap
$207.85B
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis US Small Cap Value ETF

AVUV, a U.S. small-cap value ETF, trades at $127.51, up 0.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong 2026 performance, outpacing the Russell 2000, and positioning it as a diversification tool for tech-heavy portfolios. The fund benefits from a shift toward value stocks and potential rate cut tailwinds.

The outlook for AVUV is positive, driven by small-cap value momentum and investor rotation away from large-cap concentration. Key risks include sensitivity to interest rates, regional bank exposure, and higher small-cap volatility. Analyst sentiment is optimistic, with media coverage emphasizing its role in balanced long-term strategies.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avantis US Small Cap Value ETF

AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.

Read more on AVUV

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO